PARP Combinations in Prostate Cancer: PARPi Plus Androgen Receptor Inhibitors

Download these slides from a live Webinar to gain expert insight on the rationale for combining PARP inhibitors and AR-directed therapy in mCRPC including the latest evidence from ASCO GU 2021.
person default
Neal D. Shore, MD, FACS
Format: Microsoft PowerPoint (.ppt)
File Size: 353 KB
Released: February 19, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
AstraZeneca
Merck Sharp & Dohme Corp.
Pfizer

Related Content

Comentario de un experto sobre las terapias de combinación que utilizan inhibidores de PARP más otros agentes en el cáncer de próstata avanzado de Clinical Care Options (CCO).

Johann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD Released: February 25, 2021

Commentaire des experts sur les associations thérapeutiques utilisant les inhibiteurs PARP et d'autres agents dans le traitement du cancer avancé de la prostate, extrait de Clinical Care Options (CCO)

Johann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD Released: February 25, 2021

Downloadable slideset with key highlight data from the virtual 2021 ASCO GU Cancers Symposium provided by Clinical Care Options (CCO)

Robert Motzer, MD Daniel P. Petrylak, MD Released: February 25, 2021

Downloadable slideset reviewing the latest evidence on PARP inhibitor monotherapy in metastatic CRPC, from Clinical Care Options (CCO)

Charles J. Ryan, MD Released: February 19, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue